ACTRN12611000418976已完成1 期
Patients with recurrent high grade gliomas treated with lapatinib plus temozolomide combination to investigate the safety and efficacy of the combination
Hellenic Cooperative Oncology Group0 个研究点目标入组 66 人开始时间: 2011年4月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Written informed consent 2. Age >18 years 3. Radiographic evidence of recurrent glioma (Grade IV glioblastoma multiforme or Grade III anaplastic astrocytoma). Patients should have achieved Complete Response (CR), Partial Response (PR) or Stable Disease (SD) with prior treatment with radiation (RT)/ temozolomide (adjuvant or 1st line setting). Early recurrence patients may be included in the phase I study. 4. Measurable disease at screening according to Response Evaluation Criteria In Solid Tumors (RECIST) 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 6. Adequate haematological function (Absolute Neutrophils Count>=1.5 x 10^9/Litre (L), Platelet count>=100 x 10^9/L and Haemoglobin>=9grams per deciliter (g/dL) 7. Adequate liver and renal function (Total bilirubin <1.5 x upper limit of normal, aspartate aminotransferase (AST), Alanine transaminase (ALT) <2.5x Upper Limit of Normal (ULN) in patients (pts) without liver metastases; <5xULN in pts with liver metastases, serum creatinine <=1.25xULN or calculated creatinine clearance >=50 Millilitre per minute (mL/min) 8. Left Ventricular Ejection Fraction (LVEF) within institutional normal range 9. All patients must have archived tumour tissue available for translational research.10. Drugs and several herbal constituents (e.g. bergamontin and glabridin), which are inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4) must not be taken within 10 days prior to initiation of treatment and are prohibited while the patient is being treated with lapatinib 11. If a patient requires anticoagulant therapy the patient may remain on study but should be monitored carefully.
排除标准
- •1. Pregnant or lactating women
- •2. Clinically significant non-controlled cardiovascular disease
- •3. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment
- •4. Prior treatment with Epidermal Growth Factor Receptors (EGFR) inhibitors will not be allowed
- •5. Known hypersensitivity to drugs chemically related to lapatinib
- •6. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
- •7. Treatment with Enzyme-Inducing Anti-Epileptic Drugs (EIAEDs) will be excluded, use of valproate will be permitted.
- •8. Patients will be excluded if unable to swallow tablets.
- •9. Active infection.
研究者
相似试验
尚未招募
1 期
Clinical trial for recurrent malignant gliomas using boron neutron capture therapy and bevacizumabJPRN-UMIN000013419Dept. of Neurosurgery, Osaka Medical College50
进行中（未招募）
不适用
First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study. - NAGlioblastoma MultiformeEUCTR2009-013406-13-CZMasaryk University
Available
不适用
Glioblastoma and Individualized TherapiesGlioma, MalignantNCT05356312Zentrum fur Humangenetik Tuebingen
进行中（未招募）
1 期
Study to evaluate the potentiation effect of radiotherapy by AGuIX nanoparticles for the treatment of persistent glioblastomaPersistent Glioblastoma Multiforme, grade IVMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003774-32-ITDIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA30
已完成
2 期
Pilot study of nab-Paclitaxel in combination with capecitabine as second line treatment of advanced biliary cancer.advanced biliary cancerCancer - Biliary tree (gall bladder and bile duct)ACTRN12615000504516Illawarra and Shoalhaven Local Health District10